BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Ropeginterferon alfa-2b (Besremi) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Ropeginterferon alfa-2b (Besremi)\, from 
 ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06770842-9910@assetmemo.bio
DTSTAMP:20261121T005953Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Ropeginterferon alfa-2b (Besremi): Phase 2 readout est. (NCT0677084
 2)
DESCRIPTION:Ropeginterferon alfa-2b (Besremi)\, phase 2\, Myelofibrosis.\nS
 tudy: Ropeginterferon Alfa 2b Plus Ruxolitinib for Myelofibrosis\nEstimate
 d primary completion: December 2026. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/ropeginterferon-alfa-2b-besremi#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT06770842
URL:https://assetmemo.bio/drug/ropeginterferon-alfa-2b-besremi#upcoming-eve
 nts
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06468033-9910@assetmemo.bio
DTSTAMP:20261121T005953Z
DTSTART;VALUE=DATE:20271118
DTEND;VALUE=DATE:20271119
SUMMARY:Ropeginterferon alfa-2b (Besremi): Phase 3 readout est. (NCT0646803
 3)
DESCRIPTION:Ropeginterferon alfa-2b (Besremi)\, phase 3\, Myelofibrosis.\nS
 tudy: P1101 in Treating Patients With Early PMF or Overt PMF at Low or Int
 ermediate-1 Risk\nEstimated primary completion: 18 November 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/ropeginterferon-alfa-2b-besre
 mi#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 6468033
URL:https://assetmemo.bio/drug/ropeginterferon-alfa-2b-besremi#upcoming-eve
 nts
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06514807-9910@assetmemo.bio
DTSTAMP:20261121T005953Z
DTSTART;VALUE=DATE:20280315
DTEND;VALUE=DATE:20280316
SUMMARY:Ropeginterferon alfa-2b (Besremi): Phase 3 readout est. (NCT0651480
 7)
DESCRIPTION:Ropeginterferon alfa-2b (Besremi)\, phase 3.\nStudy: A Study to
  Evaluate the Efficacy and Safety of Ropeginterferon Alfa-2b in Essential 
 Thrombocythaemia Patients\nEstimated primary completion: 15 March 2028. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/ropeginterferon-alfa-2b
 -besremi#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT06514807
URL:https://assetmemo.bio/drug/ropeginterferon-alfa-2b-besremi#upcoming-eve
 nts
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07047885-9910@assetmemo.bio
DTSTAMP:20261121T005953Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Ropeginterferon alfa-2b (Besremi): Phase 1 readout est. (NCT0704788
 5)
DESCRIPTION:Ropeginterferon alfa-2b (Besremi)\, phase 1.\nStudy: Ropeginter
 feron in Patients w/Cutaneous T-Cell Lymphoma (CTCL)\nEstimated primary co
 mpletion: June 2028. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 ropeginterferon-alfa-2b-besremi#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07047885
URL:https://assetmemo.bio/drug/ropeginterferon-alfa-2b-besremi#upcoming-eve
 nts
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07646821-9910@assetmemo.bio
DTSTAMP:20261121T005953Z
DTSTART;VALUE=DATE:20281211
DTEND;VALUE=DATE:20281212
SUMMARY:Ropeginterferon alfa-2b (Besremi): Phase 1/2 readout est. (NCT07646
 821)
DESCRIPTION:Ropeginterferon alfa-2b (Besremi)\, phase 1/2.\nStudy: A Phase 
 1b/2 Study of Ropeginterferon Alfa-2b Added to Azacitidine in MDS/AML With
  TP53 Mutations\nEstimated primary completion: 11 December 2028. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/ropeginterferon-alfa-2b-besrem
 i#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 646821
URL:https://assetmemo.bio/drug/ropeginterferon-alfa-2b-besremi#upcoming-eve
 nts
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07053904-9910@assetmemo.bio
DTSTAMP:20261121T005953Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Ropeginterferon alfa-2b (Besremi): Phase 1 readout est. (NCT0705390
 4)
DESCRIPTION:Ropeginterferon alfa-2b (Besremi)\, phase 1.\nStudy: Phase I Op
 en-Label Study of P1101 Followed by P1801 in Advanced Solid Tumors\nEstima
 ted primary completion: 31 December 2028. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/ropeginterferon-alfa-2b-besremi#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT07053904
URL:https://assetmemo.bio/drug/ropeginterferon-alfa-2b-besremi#upcoming-eve
 nts
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07521046-9910@assetmemo.bio
DTSTAMP:20261121T005953Z
DTSTART;VALUE=DATE:20290831
DTEND;VALUE=DATE:20290901
SUMMARY:Ropeginterferon alfa-2b (Besremi): Phase 1 readout est. (NCT0752104
 6)
DESCRIPTION:Ropeginterferon alfa-2b (Besremi)\, phase 1\, Myelofibrosis.\nS
 tudy: Tolerability of Ropeginterferon Alfa-2b Add-on to Ongoing Ruxolitini
 b Therapy in Myelofibrosis\nEstimated primary completion: August 2029. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/ropeginterferon-alfa-2b-
 besremi#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07521046
URL:https://assetmemo.bio/drug/ropeginterferon-alfa-2b-besremi#upcoming-eve
 nts
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07269470-9910@assetmemo.bio
DTSTAMP:20261121T005953Z
DTSTART;VALUE=DATE:20291101
DTEND;VALUE=DATE:20291102
SUMMARY:Ropeginterferon alfa-2b (Besremi): Phase 2 readout est. (NCT0726947
 0)
DESCRIPTION:Ropeginterferon alfa-2b (Besremi)\, phase 2.\nStudy: Phase II S
 tudy Assessing the Safety and Efficacy of Dasatinib in Combination With Ro
 peginterferon in Patients With Newly Diagnosed Chronic Myeloid Leukemia in
  Chronic Phase\nEstimated primary completion: 1 November 2029. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/ropeginterferon-alfa-2b-besremi#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0726
 9470
URL:https://assetmemo.bio/drug/ropeginterferon-alfa-2b-besremi#upcoming-eve
 nts
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07468916-9910@assetmemo.bio
DTSTAMP:20261121T005953Z
DTSTART;VALUE=DATE:20320130
DTEND;VALUE=DATE:20320131
SUMMARY:Ropeginterferon alfa-2b (Besremi): Phase 2 readout est. (NCT0746891
 6)
DESCRIPTION:Ropeginterferon alfa-2b (Besremi)\, phase 2.\nStudy: Ropeginter
 feron Alfa-2b for the Treatment of Myelodysplastic Syndrome/Myeloprolifera
 tive Neoplasm Overlap Syndromes and Chronic Myelomonocytic Leukemia\nEstim
 ated primary completion: 30 January 2032. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/ropeginterferon-alfa-2b-besremi#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT07468916
URL:https://assetmemo.bio/drug/ropeginterferon-alfa-2b-besremi#upcoming-eve
 nts
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
